2009
Transient cocaine-associated behavioral symptoms rated with a new instrument, the scale for assessment of positive symptoms for cocaine-induced psychosis (SAPS-CIP).
Tang YL, Kranzler HR, Gelernter J, Farrer LA, Pearson D, Cubells JF. Transient cocaine-associated behavioral symptoms rated with a new instrument, the scale for assessment of positive symptoms for cocaine-induced psychosis (SAPS-CIP). American Journal On Addictions 2009, 18: 339-45. PMID: 19874151, PMCID: PMC2878659, DOI: 10.3109/10550490903077937.Peer-Reviewed Original ResearchConceptsCocaine-induced psychosisProportion of subjectsBehavioral symptomsSAPS-CIPAgitated behaviorsPositive symptomsStereotyped behaviorSevere behavioral symptomsSexual behaviorCocaine-dependent subjectsCommon vulnerability factorsChronic useSeverity scorePsychotic symptomsCocaine useSymptomsPsychosisSubstantial minorityCurrent reportSubjectsCocaineHallucinations
2005
Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP)
Cubells JF, Feinn R, Pearson D, Burda J, Tang Y, Farrer LA, Gelernter J, Kranzler HR. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). Drug And Alcohol Dependence 2005, 80: 23-33. PMID: 15894433, DOI: 10.1016/j.drugalcdep.2005.03.019.Peer-Reviewed Original Research
1990
Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures
Peters J, Van Kammen D, Gelernter J, Yao J, Shaw D. Neuropeptide Y-like immunoreactivity in schizophrenia Relationships with clinical measures. Schizophrenia Research 1990, 3: 287-294. PMID: 2178001, DOI: 10.1016/0920-9964(90)90012-v.Peer-Reviewed Original ResearchConceptsCSF NPY-liNPY-LINeuropeptide YLike immunoreactivityDrug-free chronic schizophrenic patientsDrug-free patientsChronic schizophrenic patientsStructural brain abnormalitiesDrug-free controlsAspects of schizophreniaHaloperidol withdrawalPatient's CSFHaloperidol treatmentMaintenance treatmentBrain abnormalitiesClinical measuresCT scanSchizophrenic patientsPositive symptomsPatientsLonger durationSignificant differencesSignificant increasePresent findingsImmunoreactivity